Drug Profile


Alternative Names: MD 20051B; SL 920241

Latest Information Update: 22 Nov 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antiemetics; Anxiolytics; Benzamides; Gastrokinetics
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders
  • Discontinued Nausea and vomiting

Most Recent Events

  • 22 Nov 1999 Discontinued-II for Emesis in France (Unknown route)
  • 22 Nov 1999 No-Development-Reported for Anxiety disorders in United Kingdom (Unknown route)
  • 27 Aug 1999 Sanofi and Synthélabo have now merged to form Sanofi-Synthélabo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top